Endpoints News
Even more IPOs on tap Read in browser
Endpoints News
Thank you for reading, Test Researcher!
basic
UPGRADE
M T W Th Fri
9 October, 2026
$142 billion in 340B medicine markups
Nearly 60% of 340B spending is driven by medicine markups. The federal 340B program is now a $244B behemoth yet there is little oversight or accountability, unlike most federal programs. Learn more.
sponsored by PhRMA
presented by ALTASCIENCES
The Patent Clock Is Al­ready Run­ning. Why De­vel­op­ment Speed Is Al­so a Com­mer­cial Strat­e­gy
top stories
1. New data on RevMed’s Rasonque leave potential opening for other treatments
2. Acting general counsel at HHS has left the department
3.
news briefing
City Therapeutics targets $158M IPO; Iambic seeks $135M Nasdaq debut
4. Exclusive: AI startup Chai lands GSK deal, its sixth pharma partner in nine months
5. TRexBio prices $117M IPO for Tregs as Retension lands $45M Nasdaq debut for hypertension
6.
peer review
Viking commercial chief is out in a hurry; Gilead looks to BeOne exec for China expansion
more stories
• 
Karen Weintraub
.

Revolution Medicines' standing-ovation-worthy KRAS therapy for pancreatic cancer might leave room for more targeted KRAS drugs, new data suggest. Lei Lei Wu has the details.

.
Karen Weintraub
Deputy Editor, Endpoints News
1
by Lei Lei Wu

Pa­tients with the most com­mon KRAS mu­ta­tion in pan­cre­at­ic can­cer ap­peared to have a low­er re­sponse rate than the over­all pa­tient pop­u­la­tion with Rev­o­lu­tion Med­i­cines’...

Read the full story
2
by Max Bayer

The act­ing gen­er­al coun­sel at HHS, Bob Fos­ter, is no longer at the agency.

When End­points Newscon­tact­ed Fos­ter through his gov­ern­ment email, it re­ceived...

Read the full story
Endpoints webinars
Oct 13
11:00 am ET
Commercial excellence and AI - a ripple, wave or a tsunami
ZS
Oct 15
1:00 pm ET
Insights into Polycystic Kidney Disease: The Potential of Clinicogenomic Data
Natera
Oct 20
11:00 am ET
Intelligent oversight and orchestration: How mission control is redefining R&D decision-making
ZS
Oct 21
11:00 am ET
From prediction to decision: Digital twins and predictive modeling in clinical development
Flatiron
Oct 22
11:00 am ET
A new model for clinical research – Expanding community trial access
Parexel
Oct 28
10:30 am ET
The evolution of MRD: From molecular detection to clinical decisions
ABBOTT
News Briefing: Quick hits from the biopharma web